COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
HBM Healthcare Investments' portfolio company Swixx BioPharma boosts sales and profits through strategic acquisition in Latin America
HBM Healthcare Investments' portfolio company Swixx BioPharma acquires Laboratorios Biopas Group in Latin America, boosting sales and profits. The strategic acquisition expands Swixx's footprint and market presence -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
HBM Healthcare Investments achieves a balanced result in the 2023/2024 financial year
HBM Healthcare Investments almost broke even in the 2023/2024 financial year with a slight loss of CHF 1 million. Mixed portfolio performance with a 0.3% increase in NAV. Unfavourable currency developments affected results. Board proposes unchanged par value repayment of CHF 7.50 per share
